Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis
company, is pleased to report to their shareholders that the choice of
our initial cannabis-based pharmaceutical for FDA clinical trials has
been made. The Company has reported several possible drugs for
FDA clinical trials. Based on extensive studies, the Company has decided
to contract with a group based in Colorado to handle the Company’s FDA
filings. Appropriate announcements will be made when the contracts are
finalized.
“We
have decided to give this interim report due to the overwhelming
interest we have been receiving in the US and around the World from
existing and potential investors. In the next few days we will announce
more specifics regarding our first FDA application.”
Dr. Robert Melamede, President & CEO Cannabis Science Inc., stated,
“We have made great progress and this is just the beginning. We are in
the final stages before Cannabis Science files with the FDA for clinical
trials. There is a massive amount of Cannabis research that is
available. Cannabis is one of the only drugs that have little or no
negative side effects when used medically. We will request that the FDA
consider this and other facts when examining our application. We have a
great team of FDA experts and scientific minds to make sure that every
step we take is inline with FDA requirements”
Richard Cowan, Cannabis Science Inc., CFO & Director stated, “We
have decided to give this interim report due to the overwhelming
interest we have been receiving in the US and around the World from
existing and potential investors. In the next few days we will announce
more specifics regarding our first FDA application."
Cannabis Science has accomplished and will be announcing shortly
several critical steps to determine its FDA protocols and drug
submission:
1. Successfully identified and negotiated medical cannabis
growing operations to provide material for basic and clinical research.